Cannabis Science Conference West 2019 Analytical Cannabis Keynote Speaker, Day 1
Dr. Markus Roggen, CEO, Complex Biotech Discovery Ventures, discusses his keynote talk “Collaborative Research for Fundamental Insight into Cannabis Production” from the 2019 Cannabis Science Conference West.
Dr. Markus Roggen, CEO, Complex Biotech Discovery Ventures, will give a keynote talk today in Exhibit Hall B at 9:10 a.m. The talk is titled “Collaborative Research for Fundamental Insight into Cannabis Production.” Roggen recently spoke to us about his talk and what he hopes attendees will learn from it.
Can you give us a little preview of your keynote talk for the 2019 Cannabis Science Conference West? Dr. Markus Roggen: In this keynote, I present Complex Biotech Discovery Ventures (CBDV’s) latest data and findings, and discuss the reason two specific factors are key, not only to our progress, but to the entire cannabis industry’s future: A collaborative, multidisciplinary research team, and a focus on science fundamentals instead of bright, shiny things. This presentation will not be a commercial pitch, but a walk-through of the different fundamental factors governing cannabis production. As it is considered for a keynote slot, I plan to mix hard data from our lab with a philosophical call to action to jointly move the field forward. Our team has undertaken statistical analyses of supercritical CO2 and ethanol extraction and performed computational studies on THCA and CBDA decarboxylation. We have also developed in-process analytical tools and protocols that we see as vital to the growth of the industry. In the spirit of collaboration, our team will make available an optimization template for producer to use in their extraction operation.
What do you hope attendees will take away from your keynote?
Roggen: Cannabis science is lacking behind other industrial fields, and to play catchup we have to put in a concerted effort into fundamental cannabis research. And my argument here is that we need to collaborate on research to quickly close the knowledge gap. The cannabis industry comes with a history of secrecy, but only open, transparent and communal research will enable us to build a solid foundation of scientific understanding and build trust with the general public.
What are you hoping to learn or take away from this year’s conference? Are there any other talks you plan to attend?
Roggen: It is nearly impossible to pick out one talk that I am especially looking forward to. All the talks in the analytical section this year are very interesting to me as they describe work into tracking molecules in cannabis of various forms. Conor Jenkins presents work in comprehensive profiling of cannabis molecules, Dr. Sven Ehlert talks about analyzing cannabis smoke for its molecular make-up, and Jiries Meehan-Atrash shows work into studying degradation of cannabis extracts. And that is just the morning session. I am lucky my presentation is early, so that I can focus on learning from my colleagues.
Cannabis, US Presidential Election 2024, and Beyond: A Roundtable Discussion, Part II
December 17th 2024With the recent 2024 presidential election behind us, the future of cannabis still has many unknowns moving forward and questions still to be discussed. In this roundtable discussion with four knowledgeable industry leaders, we explore the nuanced political landscape of cannabis legalization and rescheduling in the context of the election, including state and federal policies and possible paths forward for testing standardization. Join us in the second part of a compilation of responses from Kim Anzarut, CQA, CP-FS, CEO of Allay Consulting; Susan Audino, PhD, founder of S.A. Audino & Associates, LLC; Zacariah Hildenbrand, PhD, research Professor at the University of Texas at El Paso; and David Vaillencourt, CEO of The GMP Collective.
Cannabis, US Presidential Election 2024, and Beyond: A Roundtable Discussion, Part I
December 16th 2024With the recent 2024 presidential election behind us, the future of cannabis still has many unknowns moving forward and questions still to be discussed. In this roundtable discussion with four knowledgeable industry leaders, we explore the nuanced political landscape of cannabis legalization and rescheduling in the context of the election. We discuss what drives support or opposition from both sides of the aisle, the complexities of balancing state and federal priorities, and more. Join us in the first part of a compilation of responses from Kim Anzarut, CQA, CP-FS, CEO of Allay Consulting; Susan Audino, PhD, founder of S.A. Audino & Associates, LLC; Zacariah Hildenbrand, PhD, research Professor at the University of Texas at El Paso; and David Vaillencourt, CEO of The GMP Collective.
Empowering Women in Cannabis: Susan Audino, PhD, on Inclusivity, Integrity, and Industry Challenges
December 11th 2024Founder of S. A. Audino & Associates, LLC, Susan Audino, PhD, recently co-founded Saturn Scientific, LLC, a collaboration of five experienced individuals providing unbiased evaluations on the data and science for stakeholders in the cannabis industry. In this interview with Cannabis Science and Technology, Dr. Audino shares her unexpected path into analytical science and the cannabis industry as well as the obstacles she’s faced throughout her career. She highlights the gender bias she’s observed, such as unequal recognition of credentials and workplace challenges, while advocating for inclusivity and mentorship to empower women in science. Additionally, Dr. Audino recounts her experiences of navigating the male-dominated cannabis space, pushing for transparency, collaboration, and integrity in laboratory practices. Ultimately, Audino believes fostering mutual respect and knowledge-sharing is vital for the industry’s growth and resilience.
Collaboration, Gender Diversity, and Progress: Julie Kowalski on Advancing Cannabis Science
December 10th 2024In this interview with Cannabis Science and Technology, Julie Kowalski, an experienced analytical chemist, discusses her path into the cannabis industry, starting with early work in gas chromatography. Kowalski reflects on her perspectives as a female scientist, highlighting biases she’s experienced and the benefits of gender inclusivity in the cannabis space. Greater unity and professionalism could benefit the industry as a whole, she explains. She also encourages collaboration and more women in leadership positions in order to build a stronger scientific community, and also urges women to advocate for themselves, noting that women in cannabis face unique obstacles but often demonstrate consensus-building strategies and solutions.
Gender Diversity and Innovation in the Cannabis Space: Insights from Tess Eidem, PhD
December 9th 2024Cannabis Science and Technology sat down with Tess Eidem, PhD, PCQI, member of Saturn Scientific, LLC, to discuss her journey from antibiotic research to cannabis microbiology and her observations throughout her career. Dr. Eidem highlights challenges women face in this male-dominated industry, including limited representation in leadership roles and frequent experiences of bias and discrimination. She emphasizes the importance of gender diversity in fostering innovation, improving product safety, and addressing women’s health needs in cannabis applications. Her advice to women scientists is to build strong professional relationships and carefully evaluate work environments to advance their careers in this evolving and often challenging space.
Inside the University of Maryland School of Pharmacy’s Graduate Program in Medical Cannabis
September 16th 2024Leah Sera, PharmD, MA, the co-program director for the University of Maryland School of Pharmacy’s Graduate Studies in Medical Cannabis program sat down with Cannabis Science and Technology to discuss higher education in medical cannabis.
